RESUMO
Drug reaction with eosinophilia and systemic symptom (DRESS) is a severe adverse drug-induced reaction. Commonly related to anticonvulsant and allopurinol, DRESS can affect both adults and children. Cefotaxime is rarely associated with DRESS, especially with children. We report a cefotaxime-induced DRESS in a child and emphasize the role of allergological work-up to point out the culprit drug in exploring cross-reactivity and identifying a possible cosensitization. A 2-year-old boy was treated with cefotaxime, vancomycin and metronidazole for acute otomastoiditis. Metronidazole was withdrawn and vancomycin was changed by teicoplanin 10 and 15 days later, respectively. Nineteen days after ongoing cefotaxime and 4 days after teicoplanin intake, the patient developed hyperthermia, a widespread exanthema, facial oedema with neither mucosal involvement nor palpable lymphadenopathy. Biological tests revealed eosinophilia, atypical lymphocytes, mild cytolysis and a high lactate dehydrogenase level. Serological tests for viral and bacterial infections were negative. DRESS was suspected and the 2 antibiotics were withdrawn. Intradermal tests (IDT) were carried out 2 months later with cefotaxime and teicoplanin. They revealed a positive result at 48-hour reading. To assess cross-reactivity among ß-lactams, IDT to penicillins (benzylpenicillin, amoxicillin and oxacillin) was performed showing negative results at 48-hour reading. Nevertheless, IDT to cephalosporins (cefazolin, cefuroxime, ceftazidime and ceftriaxone) displayed positive results at 48-hour reading. As a result, IDT are of great interest and should be performed to confirm the role of cefotaxime and detect a potential cross-reactivity with chemically similar drugs and drugs taken before and during the episode of DRESS.
Assuntos
Síndrome de Hipersensibilidade a Medicamentos , Eosinofilia , Masculino , Adulto , Criança , Humanos , Pré-Escolar , Cefotaxima/efeitos adversos , Teicoplanina/efeitos adversos , Cefalosporinas/efeitos adversos , Vancomicina/efeitos adversos , Síndrome de Hipersensibilidade a Medicamentos/diagnóstico , Síndrome de Hipersensibilidade a Medicamentos/etiologia , Metronidazol , Eosinofilia/induzido quimicamente , Eosinofilia/diagnósticoRESUMO
OBJECTIVES: A prospective evaluation of nonchemotherapy drug-induced agranulocytosis (DIA) cases, which are infrequent in the pediatric population. We characterize agranulocytosis cases and assess lab test differences between drug- and nondrug-induced agranulocytosis. METHODS: Through our Prospective Pharmacovigilance Program from Laboratory Signals at Hospital we detected pediatric agranulocytosis cases from July 2007 to December 2010. This program estimates the incidence, drug causality, clinical features, outcomes of DIA pediatric cases, and assesses laboratory differences with respect to non-DIA. RESULTS: We detected 662 agranulocytosis in 308 pediatric patients, of which 14 were caused by nonchemotherapy drugs. The incidence rate of DIA for 10,000 pediatric patients was 3.92 (Poisson 95% confidence interval 1.09-8.77); 78.6% of DIA cases occurred in patients younger than 3 years. The final outcome was recovery without sequela in all cases. The pharmacologic group most frequently implicated was antimicrobial drugs (11 drugs), 7 of which were beta-lactams. The drugs most frequently suspected were cefotaxime and vancomycin (3 cases each). We found 3 drugs (cloperastine, codeine, and enoxaparin) not previously described to induce DIA. Automatic linear modeling (n = 56, R2 = 45.2%) showed a significant inverse association with platelets (R2 = 17.5%), hemoglobin, and alanine transaminase, and a direct association with red cell distribution (R2 = 16.2%). A generalized linear model (Type III, n = 1188; DIA, n = 86; likelihood ratio chi-squared = 156.16) retained eosinophils (p <.001), platelets (p <.001), total serum proteins (p <.001), and hemoglobin (p =.039). CONCLUSIONS: We found a higher incidence of DIA in children than previously described. Our findings also suggest an immune-mediated destruction or myeloid toxicity, possibly facilitated by an increase in drug exposure.
Assuntos
Agranulocitose , Cefotaxima/efeitos adversos , Codeína/efeitos adversos , Enoxaparina/efeitos adversos , Piperidinas/efeitos adversos , Vancomicina/efeitos adversos , Fatores Etários , Agranulocitose/induzido quimicamente , Agranulocitose/diagnóstico , Agranulocitose/epidemiologia , Agranulocitose/terapia , Cefotaxima/administração & dosagem , Criança , Pré-Escolar , Codeína/administração & dosagem , Enoxaparina/administração & dosagem , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Piperidinas/administração & dosagem , Estudos Prospectivos , Vancomicina/administração & dosagemRESUMO
BACKGROUND AND PURPOSE: Our aim was to evaluate the available evidence for pharmacological treatment of acute Lyme neuroborreliosis as a basis for evidence-based clinical recommendations in a systematic review. METHODS: A systematic literature search of Medline, EMBASE, the Cochrane Library and three trial registries was performed. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were evaluated. Risk of bias was assessed using the Cochrane risk of bias tools. The primary outcome was 'residual neurological symptoms' whilst the secondary outcomes were disability, quality of life, pain, fatigue, depression, cognition, sleep, adverse events and cerebrospinal fluid pleocytosis. The quality of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: After screening 5779 records, eight RCTs and eight NRS were included. Risk of bias was generally high. No statistically significant difference was found between doxycycline and beta-lactam antibiotics in a meta-analysis regarding residual neurological symptoms at 4-12 months [risk ratio (RR) 1.27, 95% confidence interval (CI) 0.98-1.63, P = 0.07] or adverse events (RR 0.82, 95% CI 0.54-1.25, P = 0.35). Significantly fewer neurological symptoms for cefotaxime compared with penicillin were found (RR 1.81, 95% CI 1.10-2.97, P = 0.02). Adverse events were significantly fewer for penicillin (RR 0.56, 95% CI 0.38-0.84, P = 0.005). CONCLUSIONS: Evidence regarding pharmacological treatment of acute Lyme neuroborreliosis is scarce and therefore insufficient to recommend preference of beta-lactam antibiotics over doxycycline or vice versa. However, due to considerable imprecision, relevant differences between treatments cannot be excluded. No evidence suggesting benefits of extended antibiotic treatments could be identified. Further well-designed trials are needed. Individual treatment decisions should address patients' preferences and individual conditions like prior allergic reactions.
Assuntos
Antibacterianos/farmacologia , Cefotaxima/farmacologia , Doxiciclina/farmacologia , Neuroborreliose de Lyme/tratamento farmacológico , Penicilinas/farmacologia , beta-Lactamas/farmacologia , Antibacterianos/administração & dosagem , Antibacterianos/efeitos adversos , Cefotaxima/administração & dosagem , Cefotaxima/efeitos adversos , Doxiciclina/administração & dosagem , Doxiciclina/efeitos adversos , Feminino , Humanos , Penicilinas/administração & dosagem , Penicilinas/efeitos adversos , beta-Lactamas/administração & dosagem , beta-Lactamas/efeitos adversosRESUMO
BACKGROUND: Multidrug-resistant Escherichia coli infections are a global health challenge, notably in North America, Europe, Asia, and Africa. This systematic review and meta-analysis evaluates the effectiveness and safety of cefotaxime combined with avibactam, aiming to mitigate these infections' impact and lessen their burden on healthcare systems worldwide. METHODS: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and PICO frameworks, we conducted a comprehensive literature search across 4 primary databases on May 6, 2023. Studies evaluating the efficacy and safety of cefotaxime and avibactam were included. Key outcomes included treatment success, adverse effects, and microbiological eradication. Quality assessment utilized the Cochrane Collaboration Risk of Bias instrument. Heterogeneity was analyzed using chi-square statistics and the I2 index. Both fixed- and random-effects models were applied as appropriate. Publication bias was rigorously evaluated using Egger linear regression test and funnel plot analysis, ensuring the study's integrity and reliability. RESULTS: The clinical cure rate derived from 8 studies showed no significant difference between the treatment groups (odds ratio [OR]â =â 1.97, 95% CI: 0.69 to 1.36, Pâ =â .86). Analysis of the bacterial clearance rate from the 5 studies also indicated no significant difference (ORâ =â 0.97, 95% CI: 0.42 to 2.25, Pâ =â .36). Notably, a reduced mortality rate favoring the experimental group was observed in 6 studies (ORâ =â 0.64, 95% CI: 0.44 to 0.92, Pâ =â .012). Comprehensive sensitivity analyses and the assessment of publication bias strengthened the reliability of the results. CONCLUSIONS: Ceftazidime combined with avibactam significantly reduced mortality among patients with multidrug-resistant Escherichia coli infections, indicating its potential as a therapeutic option, especially for carbapenem-resistant Enterobacteriaceae. However, extensive large-scale clinical trials are required to validate these findings.
Assuntos
Antibacterianos , Infecções por Escherichia coli , Humanos , Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Compostos Azabicíclicos/efeitos adversos , Compostos Azabicíclicos/uso terapêutico , Cefotaxima/efeitos adversos , Cefotaxima/uso terapêutico , Ceftazidima/efeitos adversos , Ceftazidima/uso terapêutico , Combinação de Medicamentos , Escherichia coli , Infecções por Escherichia coli/tratamento farmacológico , Reprodutibilidade dos TestesRESUMO
OBJECTIVE: This study aims to explore the effects of cefixime on immune functions and inflammatory factors in children with urinary tract infection and to investigate its nursing strategies. METHODS: A total of 161 children with urinary tract infection who were diagnosed in our hospital from November 2019 to November 2021 were selected. All children were treated with cefixime and received targeted nursing strategies. The indices of immune functions and the levels of inflammatory factors were compared before and after the treatment. The satisfaction degree of children's family members, recurrence rate and incidence of adverse reactions were measured. RESULTS: The levels of CD3+, CD4+ and CD4+/CD8+ in children after the treatment were significantly higher but the CD8+ level was significantly lower than those before the treatment (p < 0.001). The levels of C-reactive protein, tumour necrosis factor-α and interleukin-6 after the treatment were lower than those before the treatment (p < 0.001). The average score of nursing satisfaction of children's family members was (84.53 ± 13.65) points, with the total satisfaction degree of 90.68% (146/161). Within 6 months after the treatment, only six children had urinary tract infection again and the recurrence rate was 3.73% (6/161). During the treatment, seven children had adverse reactions to the drug, with an incidence rate of 4.35% (7/161). CONCLUSIONS: Cefixime can improve the immune function of children with urinary tract infection and reduce the levels of inflammatory factors. The implementation of targeted nursing strategies can improve clinical satisfaction and reduce the recurrence rate of the disease and thus can be helpful to establish a comprehensive and efficient clinical program for children with urinary tract infection.
Assuntos
Cefotaxima , Infecções Urinárias , Criança , Humanos , Cefixima/uso terapêutico , Cefotaxima/efeitos adversos , Infecções Urinárias/tratamento farmacológico , Administração Oral , ImunidadeRESUMO
We report two cases, one of a 52-year-old man and one of a 32-year-old man, who were treated with cefotaxime. On day 23 and day 28 of the treatment, respectively, the patients manifested clinically with fever, pruriginous skin rash, and facial edema. Blood tests showed marked eosinophilia and atypical lymphocytosis for both patients, and hepatic cytolysis only in the second patient. Cefotaxime was discontinued in both patients; the clinico-biological picture improved gradually and completely disappeared approximately 4 weeks later. Six weeks after complete recovery, both patients underwent intradermal testing which was positive to cefotaxime (2 mg/ml) at the 48-hour reading and negative to benzylpenicillin, amoxicillin, and cefazolin at the 20-minute and 48-hour readings. These clinical pictures suggest drug rash with eosinophilia and systemic symptoms (DRESS) induced by cefotaxime. To the best of our knowledge, only one case of cefotaxime-induced DRESS has been reported in the medical literature. Thus, we add two new cases of cefotaxime-induced DRESS and emphasize the usefulness and safety of intradermal testing in establishing the diagnosis.
Assuntos
Antibacterianos/efeitos adversos , Cefotaxima/efeitos adversos , Edema , Eosinofilia , Linfocitose , Dermatopatias , Adulto , Antibacterianos/administração & dosagem , Cefotaxima/administração & dosagem , Edema/sangue , Edema/induzido quimicamente , Edema/patologia , Eosinofilia/sangue , Eosinofilia/induzido quimicamente , Eosinofilia/patologia , Humanos , Linfocitose/sangue , Linfocitose/induzido quimicamente , Linfocitose/patologia , Masculino , Pessoa de Meia-Idade , Dermatopatias/sangue , Dermatopatias/induzido quimicamente , Dermatopatias/patologiaRESUMO
Recent studies have highlighted the importance of ecological interactions in dysbiosis of gut microbiota, but few focused on their role in antibiotic-induced perturbations. We used the data from the CEREMI trial in which 22 healthy volunteers received a 3-day course of ceftriaxone or cefotaxime antibiotics. Fecal samples were analyzed by 16S rRNA gene profiling, and the total bacterial counts were determined in each sample by flux cytometry. As the gut exposure to antibiotics could not be experimentally measured despite a marked impact on the gut microbiota, it was reconstructed using the counts of susceptible Escherichia coli. The dynamics of absolute counts of bacterial families were analyzed using a generalized Lotka-Volterra equations and nonlinear mixed effect modeling. Bacterial interactions were studied using a stepwise approach. Two negative and three positive interactions were identified. Introducing bacterial interactions in the modeling approach better fitted the data, and provided different estimates of antibiotic effects on each bacterial family than a simple model without interaction. The time to return to 95% of the baseline counts was significantly longer in ceftriaxone-treated individuals than in cefotaxime-treated subjects for two bacterial families: Akkermansiaceae (median [range]: 11.3 days [0; 180.0] vs. 4.2 days [0; 25.6], p = 0.027) and Tannerellaceae (13.7 days [6.1; 180.0] vs. 6.2 days [5.4; 17.3], p = 0.003). Taking bacterial interaction as well as individual antibiotic exposure profile into account improves the analysis of antibiotic-induced dysbiosis.
Assuntos
Microbioma Gastrointestinal , Antibacterianos/efeitos adversos , Bactérias/genética , Cefotaxima/efeitos adversos , Ceftriaxona/efeitos adversos , Disbiose/induzido quimicamente , Disbiose/tratamento farmacológico , Microbioma Gastrointestinal/genética , Humanos , RNA Ribossômico 16S/genéticaRESUMO
Background: ABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis. All the reported severe DIIHA were caused by drug-induced antibodies, and rare report of acute intravascular hemolysis was caused by the NIPA mechanism or ABO-HDN. Case presentation: We report the first case of acute intravascular hemolysis induced by cefotaxime sodium - sulbactam sodium (CTX - SBT) in a case of ABO-HDN which resulted in death at 55 h after birth. The mother's blood type was O and RhD-positive, and the newborn's blood type was B and RhD-positive. No irregular red blood cell (RBC) antibodies or drug-dependent antibodies related to CTX or SBT was detected in the mother's plasma and the plasma or the RBC acid eluent of the newborn. Before the newborn received CTX - SBT treatment, the result of direct antiglobulin test (DAT) was negative while anti-B was positive (2 +) in both plasma and acid eluent. After the newborn received CTX - SBT treatment, the results of DAT for anti-IgG and anti-C3d were both positive, while anti-B was not detected in plasma, but stronger anti-B (3 +) was detected in acid eluent. In vitro experiments confirmed that NIPA of SBT promoted the specific binding of maternal-derived IgG anti-B to B antigen on RBCs of the newborn, thereby inducing acute intravascular hemolysis. Conclusion: The NIPA effect of SBT promoted the specific binding of mother-derived IgG anti-B in newborn's plasma to the newborn's RBC B antigens and formed an immune complex, and then activated complement, which led to acute intravascular hemolysis. Drugs such as SBT with NIPA effect should not be used for newborns with HDN.
Assuntos
Sistema ABO de Grupos Sanguíneos/imunologia , Anemia Hemolítica/induzido quimicamente , Incompatibilidade de Grupos Sanguíneos/complicações , Cefotaxima/efeitos adversos , Eritroblastose Fetal/etiologia , Hemólise , Imunoglobulina G/imunologia , Isoanticorpos/imunologia , Sulbactam/efeitos adversos , Doença Aguda , Adsorção , Anemia Hemolítica/sangue , Reações Antígeno-Anticorpo , Incompatibilidade de Grupos Sanguíneos/sangue , Cefotaxima/administração & dosagem , Ativação do Complemento , Teste de Coombs , Eritroblastose Fetal/sangue , Membrana Eritrocítica/química , Membrana Eritrocítica/imunologia , Evolução Fatal , Feminino , Humanos , Recém-Nascido , Masculino , Troca Materno-Fetal , Gravidez , Sulbactam/administração & dosagem , Adulto JovemRESUMO
Lyme disease (LD) is a heavy public health burden. The most common manifestations of LD include erythema migrans (EM), Lyme neuroborreliosis (LNB), and Lyme arthritis (LA). The efficacy and safety of antibiotics for treating LD is still controversial. Thus, we performed a network meta-analysis (NMA) to obtain more data and tried to solve this problem. We searched studies in the databases of Embase and PubMed from the date of their establishments until 22 April 2021. Odds ratios (ORs) were used to assess dichotomous outcomes. A total of 31 randomized controlled trials (RCTs) involving 2,748 patients and 11 antibiotics were included. Oral amoxicillin (1.5 g/day), oral azithromycin (0.5 g/day), injectable ceftriaxone, and injectable cefotaxime were effective for treating LD (range of ORs, 1.02 to 1,610.43). Cefuroxime and penicillin were safe for treating LD (range of ORs, 0.027 to 0.98). Amoxicillin was effective for treating EM (range of ORs, 1.18 to 25.66). Based on the results, we thought oral amoxicillin (1.5 g/day), oral azithromycin (0.5 g/day), injectable ceftriaxone, and injectable cefotaxime were effective for treating LD. Cefuroxime and penicillin were safe for treating LD. Amoxicillin was effective for treating EM. We did not observe evidence proving the advantage of doxycycline in efficacy and safety for treating LD, LA, LNB, and EM of children or adults. We did not have sufficient data to prove the significant difference of efficacy for treating LA and LNB in adults and LD in children, the significant difference of safety of oral drugs for treating LD, and the significant difference of safety of drugs for treating EM. IMPORTANCE Some previous studies investigated the efficacy and safety of antibiotics for treating Lyme disease (LD). However, due to technical limitations, several questions regarding the routes of drug administration and the dosages of drug are still unclear, which might be causing problems for clinicians. Hence, we performed network meta-analysis (NMA) to quantitatively analyze the clinical data published during the last 40 years. Here, we demonstrate the evidence regarding the efficacy and safety of antibiotics commonly used for treating LD in adults and children. We found that amoxicillin, azithromycin, ceftriaxone, and cefotaxime were effective for treating LD, but we did not observe significant efficacy and safety of doxycycline for treating LD.
Assuntos
Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Doença de Lyme/tratamento farmacológico , Administração Oral , Adulto , Amoxicilina/efeitos adversos , Amoxicilina/uso terapêutico , Azitromicina/efeitos adversos , Azitromicina/uso terapêutico , Borrelia burgdorferi/efeitos dos fármacos , Grupo Borrelia Burgdorferi/efeitos dos fármacos , Cefotaxima/efeitos adversos , Cefotaxima/uso terapêutico , Ceftriaxona/efeitos adversos , Ceftriaxona/uso terapêutico , Criança , Doxiciclina/efeitos adversos , Doxiciclina/uso terapêutico , Humanos , Injeções/efeitos adversos , Metanálise em Rede , Penicilinas/efeitos adversos , Penicilinas/uso terapêuticoRESUMO
Previous studies on bacterial response to antibiotics mainly focused on susceptible strains. Here we characterized the transcriptional responses of distinct cephalosporin-resistant bacteria of public health relevance to cefotaxime (CTX), a cephalosporin widely used in clinical practice. Adaptation to therapeutic concentrations of CTX (30 µg/ml) was investigated by RNA sequencing in mid-exponential phase cultures of a methicillin-resistant Staphylococcus aureus (MRSA) and two genetically diverse E. coli producing CTX-M-15 or CMY-2 ß-lactamase following genome sequencing and annotation for each strain. MRSA showed the most notable adaptive changes in the transcriptome after exposure to CTX, mainly associated with cell envelope functions. This reprogramming coincided with a transient reduction in cell growth, which also occurred in the CMY-2-producing E. coli but not in the CTX-M-15-producing strain. Re-establishment of growth in the CMY-2 producer proceeded without any notable adaptive transcriptional response, while limited reprogramming of gene transcription was observed in the CTX-M-15 producer. Our data show that the transcriptional response of CTX-resistant bacteria to CTX depends on the bacterial species, level of resistance and resistance determinant involved. Gene products induced in the presence of CTX may play an essential role for bacterial survival during therapy and merit further investigation as possible targets for potentiating CTX.
Assuntos
Cefotaxima/efeitos adversos , Escherichia coli/genética , Staphylococcus aureus Resistente à Meticilina/genética , beta-Lactamases/genética , Cefotaxima/uso terapêutico , Escherichia coli/efeitos dos fármacos , Escherichia coli/patogenicidade , Perfilação da Expressão Gênica , Humanos , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Staphylococcus aureus Resistente à Meticilina/patogenicidade , Testes de Sensibilidade Microbiana , Transcriptoma/genética , beta-Lactamas/metabolismoAssuntos
Cefotaxima/efeitos adversos , Hipersensibilidade a Drogas/tratamento farmacológico , Hipersensibilidade Tardia/induzido quimicamente , Hipersensibilidade Tardia/tratamento farmacológico , Infecções Respiratórias/tratamento farmacológico , Anafilaxia/etiologia , Anafilaxia/prevenção & controle , Cefotaxima/administração & dosagem , Protocolos Clínicos , Estado Terminal , Hipersensibilidade a Drogas/complicações , Hipersensibilidade a Drogas/fisiopatologia , Dispneia , Epinefrina/administração & dosagem , Feminino , Humanos , Hidrocortisona/administração & dosagem , Hipersensibilidade Tardia/fisiopatologia , Lactente , Infecções Respiratórias/complicações , Infecções Respiratórias/fisiopatologia , UrticáriaRESUMO
BACKGROUND: Biliary lithiasis, or sludge, and nephrolithiasis have been reported as a possible complication of ceftriaxone therapy. However, no study related to cefotaxime-induced biliary pseudolithiasis or nephrolithiasis was observed in the literature. Therefore, we investigated the comparative formation of biliary pseudolithiasis and nephrolithiasis after cefotaxime and ceftriaxone therapies. METHODS: The patients treated with ceftriaxone or cefotaxime were enrolled during the study period. Ultrasound imaging of the biliary and urinary tract was performed in all patients before and after the treatment. The patients with a positive sonographic finding at the end of treatment were followed up with monthly ultrasonography for 3 months. RESULTS: The present study showed that abnormal biliary sonographic findings were demonstrated in 18 children (20.9%) treated with ceftriaxone, 13 (15.1%) had biliary lithiasis, 5 (5.8%) had biliary sludge and 1 (1.2%) had nephrolithiasis. Abnormal biliary sonographic findings were demonstrated in only four (5.9%) children treated with cefotaxime who had biliary sludge and only one (1.5%) had nephrolithiasis. It was observed that older age was at significantly higher risk of developing biliary sludge or stone formation. Receiver operating characteristic analysis was performed to determine the residual risk and analysis found that 4.5 years was the cut-off value for age. CONCLUSIONS: The present study is unique in the literature for reporting for the first time gall bladder sludge and nephrolithiasis associated with cefotaxime use. Therefore, patients treated with cefotaxime should be monitored for serious complications like patients treated with ceftriaxone. Nevertheless, if third-generation cephalosporin is used, cefotaxime is recommended to be used rather than ceftriaxone.
Assuntos
Antibacterianos/efeitos adversos , Bile/efeitos dos fármacos , Cefotaxima/efeitos adversos , Ceftriaxona/efeitos adversos , Litíase/induzido quimicamente , Nefrolitíase/induzido quimicamente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Litíase/diagnóstico por imagem , Masculino , Nefrolitíase/diagnóstico por imagem , UltrassonografiaRESUMO
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare and potentially life-threatening idiosyncratic drug reaction. It presents with extensive rash, fever, lymphadenopathy, hematologic abnormalities (eosinophilia and/or atypical lymphocytosis) and internal organ involvement. It has been described in association with more than 50 drugs. To the best of our knowledge neither cefotaxime nor clindamycin has been previously reported to induce DRESS syndrome in children. Clindamycin was reported only in adults as a cause of DRESS syndrome in the literature. In this report, we aimed to present a child with DRESS syndrome that developed after cefotaxime and clindamycin treatment. A 6-year-old boy was diagnosed with the left lower lobe pneumonia and pleural effusion. Parenteral cefotaxime and clindamycin were then started, after which the patient improved clinically and was discharged 7 days later with oral amoxicillin clavulanate treatment. After four days he was readmitted to the hospital with fever and cough. Chest X-ray revealed left lower lobe pneumonia and pleural effusion. We considered that the pneumonia was unresponsive to oral antibiotic treatment, and therefore parenteral cefotaxime and clindamycin were re-administered. As a result, his clinical and radiological findings were improved within 10 days. On the 12th of day of hospitalization, the body temperature has risen to 39°C, which we considered to be caused by antibiotics and stopped antibiotic treatment. At the same day he developed generalized maculopapular erythematous rash, which was considered an allergic reaction secondary to antibiotics. Despite the antihistaminic drug administration, the clinical status quickly deteriorated with generalized edema, lymphadenopathies and hepatosplenomegaly. Laboratory tests revealed a white blood cell count of 4300/µl, a lymphocyte count of 1300/µl, a hemoglobin level of 11.2 gr/dl, a platelet count of 120.000/µl, an eosinophilia ratio of 10% on peripheral blood smear, a C-reactive protein level of 20 mg/dl, a procalcitonin level of 23.94 ng/ml and an erythrocyte sedimentation rate of 48 mm/h. Anti nuclear antibody, anti-double stranded DNA, the serologic tests for Epstein Bar virus, herpes simplex virus, parvovirus, mycoplasma, toxoplasmosis, rubella, cytomegalovirus were all found negative. Bone marrow aspiration was consistent with an autoimmune reaction. An echocardiographic examination was normal. Thoracic tomography revealed multiple enlarged axillary, supraclavicular and anterior mediastinal lymph nodes. As the patient met 8 out of 9 RegiSCAR criteria for the diagnosis of DRESS, we started pulse methyl prednisolone (30 mg/kg/day) for three days followed by 2 mg/kg/day. On the 2nd day fever resolved and cutaneous rash and edema improved. Ten days after developing eruptions the patient was discharged. To our knowledge, we report the first pediatric case of DRESS syndrome following treatment with cefotaxime and clindamycin. Pediatricians should be aware of this potential complication associated with these commonly prescribed antibiotics.
Assuntos
Antibacterianos/efeitos adversos , Cefotaxima/efeitos adversos , Clindamicina/efeitos adversos , Síndrome de Hipersensibilidade a Medicamentos/etiologia , Antibacterianos/administração & dosagem , Proteína C-Reativa/metabolismo , Cefotaxima/administração & dosagem , Criança , Clindamicina/administração & dosagem , Humanos , Masculino , Metilprednisolona/uso terapêutico , Derrame Pleural/tratamento farmacológico , Pneumonia/tratamento farmacológicoRESUMO
To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550 +/- $1,740 for cefotaxime and $3,160 +/- $1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980 +/- $1,800 for cefotaxime and $4,170 +/- $1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefotaxima/uso terapêutico , Nafcilina/uso terapêutico , Tobramicina/uso terapêutico , Infecções Bacterianas/economia , Cefotaxima/efeitos adversos , Ensaios Clínicos como Assunto/economia , Análise Custo-Benefício , Método Duplo-Cego , Honorários e Preços , Humanos , Rim/efeitos dos fármacos , Maryland , Nafcilina/efeitos adversos , Distribuição Aleatória , Análise de Regressão , Fatores de Tempo , Tobramicina/efeitos adversosRESUMO
Five patients with seizures related to imipenem administration are described. The potential of imipenem therapy to cause seizure was further studied in a mouse model and compared with the potential for seizure with penicillin and cefotaxime therapy. Penicillin caused ataxia and seizure at a mean mouse serum level of 5800 microns/mL, cefotaxime at 3400 microns/mL, and imipenem at a much lower serum concentration of 1900 microns/mL. The potent activity of imipenem therapy against bacteria, allowing for a clinical dose of only 2 g/d, is unfortunately offset by its higher propensity to induce neurologic symptoms in humans and mice at much smaller doses than would therapy with penicillin G or the cephalosporins, such as cefotaxime.
Assuntos
Cefotaxima/efeitos adversos , Imipenem/efeitos adversos , Penicilina G/efeitos adversos , Convulsões/induzido quimicamente , Idoso , Idoso de 80 Anos ou mais , Animais , Cefotaxima/administração & dosagem , Cefotaxima/toxicidade , Feminino , Humanos , Imipenem/administração & dosagem , Imipenem/toxicidade , Masculino , Camundongos , Pessoa de Meia-Idade , Estudos Multicêntricos como Assunto , Penicilina G/administração & dosagem , Penicilina G/toxicidadeRESUMO
Ceftriaxone sodium, a new cephalosporin with a very broad spectrum of action and a very long serum half-life, was administered to 127 patients in the treatment of 133 severe infections at our institution in Lausanne, Switzerland. Eighty infections had previously been treated unsuccessfully with other antimicrobials to which the pathogens were most often resistant. Sixty-five episodes were treated with two daily injections until there was an improvement in the patient's clinical condition, while 67 infections were treated from the start by a single daily injection. The results in the two groups were similar. One hundred fifteen infections (86%) were cured or improved, ten (8%) did not respond to therapy or recurred, and eight (6%) were not evaluable. The treatment was well tolerated, even by the 18 patients who received the drug for more than four weeks. The administration of a single daily dose instead of four doses as with standard antibiotic regimens produced a saving of Sfr 84,000 (+42,000) in the 127 patients. The single daily dose also made it possible to treat 25 of the 127 severely ill patients as outpatients, with a saving of Sfr 388,500 (+195,000) with respect to the hospital costs that would have been incurred for the same time period.
Assuntos
Instituições de Assistência Ambulatorial/economia , Infecções Bacterianas/tratamento farmacológico , Cefotaxima/análogos & derivados , Adolescente , Adulto , Idoso , Bactérias/efeitos dos fármacos , Cefotaxima/administração & dosagem , Cefotaxima/efeitos adversos , Cefotaxima/farmacologia , Ceftriaxona , Criança , Ensaios Clínicos como Assunto , Análise Custo-Benefício , Resistência Microbiana a Medicamentos , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Osteoarticular infection in children frequently occurs before 10 years of age. Surgical drainage is sometimes required, whereas acute osteomyelitis can be treated with antibiotic therapy alone. The duration of antibiotic therapy varies, 2 weeks is sufficient for septic arthritis, whereas 6 weeks is often required for complicated cases. Some of these antibiotic drugs present direct complications with low clinical impact in certain individuals. Hypersensitivity to these drugs causes different reactions in children. DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe and potentially life-threatening drug reaction. It is characterised by high fever, malaise, lymphadenopathy and skin rash. From a clinical perspective, these symptoms can lead to an exacerbation of the initial infectious process for which treatment was commenced. The liver is the organ most often affected in DRESS syndrome associated with haematological changes, potentially similar to sepsis. We present two cases of children with osteoarticular infections who developed DRESS syndrome after antibiotic therapy. Both patients made a complete recovery after cessation of the antibiotic drugs used.
Assuntos
Antibacterianos/efeitos adversos , Artrite Infecciosa/tratamento farmacológico , Cefotaxima/efeitos adversos , Cloxacilina/efeitos adversos , Síndrome de Hipersensibilidade a Medicamentos/etiologia , Articulação do Joelho , Osteomielite/tratamento farmacológico , Antibacterianos/uso terapêutico , Cefotaxima/uso terapêutico , Criança , Cloxacilina/uso terapêutico , Síndrome de Hipersensibilidade a Medicamentos/diagnóstico , Quimioterapia Combinada , Humanos , MasculinoRESUMO
The primary objective of this multicenter, prospective trial was to determine the safety, efficacy, and cost effectiveness of cefotaxime delivered via an ambulatory delivery system (ADS) in the treatment of patients with a variety of bacterial infections. The secondary objective was to determine the safety and efficacy of cefotaxime/ADS treatment of infections in a diabetic subgroup. A total of 238 patients (> or = 18 years) in five infection categories were enrolled from 10 sites. All patients received cefotaxime/ADS. Both global analysis and analysis of a subpopulation with diabetes mellitus were performed. Of the 211 patients who completed the study, 201 patients (95.3%) exhibited a satisfactory or improved clinical response following cefotaxime/ADS. Bacteriologic response, evaluable in 134 of 211 patients, was satisfactory in 125 of these patients (93.3%). Within the diabetes mellitus subpopulation, a satisfactory or improved clinical response was identified in 30 of 32 patients (93.8%). In conclusion, administration of cefotaxime via ADS is a well-tolerated, safe, and clinically effective treatment of serious infection and may be less expensive than inpatient intravenous antibiotic therapy.
Assuntos
Infecções Bacterianas/tratamento farmacológico , Cefotaxima/administração & dosagem , Serviços de Assistência Domiciliar , Bombas de Infusão , Cefotaxima/efeitos adversos , Complicações do Diabetes , Feminino , Humanos , Tempo de Internação , Masculino , Pessoa de Meia-IdadeRESUMO
The purpose of this study was to determine the efficacy, safety, and cost effectiveness of a third-generation cephalosporin, cefotaxime, administered via an ambulatory delivery system (ADS) in the treatment of bone and joint infections (BJI). A total of 27 BJI patients enrolled as a subgroup of a multicenter, prospective, open-label trial were administered 1-2 g of cefotaxime every 8 hours using ADS. Of these patients, 18 were evaluable, with the causative organisms identified and susceptible to cefotaxime. The evaluable group comprised 7 primary and 11 postsurgical BJI patients. Inpatient treatment followed by outpatient treatment with cefotaxime/ADS achieved a clinical success rate of 83.3%; however, the mean length of hospital stay for these patients was not substantially reduced. Administration via ADS permitted administration of several daily doses with minimal intervention by the patient. Both the drug and the delivery system were well tolerated. In conclusion, an intravenous antibiotic regimen such as cefotaxime administered via an ADS is an appropriate management option for patients with BJI. It is efficacious, well tolerated, and user friendly.
Assuntos
Artrite Infecciosa/tratamento farmacológico , Cefotaxima/administração & dosagem , Serviços de Assistência Domiciliar , Bombas de Infusão , Osteomielite/tratamento farmacológico , Artrite Infecciosa/diagnóstico , Cefotaxima/efeitos adversos , Humanos , Osteomielite/diagnóstico , Estudos ProspectivosRESUMO
The treatment of bacterial pneumonia commands a large segment of hospital resources, and economic concerns are dictating shorter hospital stays. This study was designed to determine whether outpatient therapy with intravenous (IV) antibiotics (a third-generation cephalosporin, cefotaxime, delivered via an ambulatory delivery system [ADS]) is as effective as traditional hospital management of pneumonia. A subgroup of 62 patients from three centers, with bacterial pneumonia, were enrolled in a multicenter, open-label study of outpatient IV cefotaxime therapy. Doses of cefotaxime were 1 g IV every 12 hours, 1 g IV every 8 hours, or 2 g IV every 8 hours, based on severity of infection. Of 62 patients, 53 (85%) completed the study. All 22 bacteriologically evaluable patients showed eradication of pathogen or clinical cure with no obtainable follow-up culture; no relapses, reinfections, or superinfections were reported. Overall clinical success rate was 94.8% (satisfactory 75.9%; improved 19.0%, n = 58). Average length of hospital stay was 2.3 +/- 4.83 days. In conclusion, clinical success rates with outpatient IV cefotaxime therapy were comparable to previous studies with IV cefotaxime for pneumonia treatment in the hospital. Outpatient IV antibiotic therapy has the potential to significantly reduce length of hospital stay for pneumonia without sacrificing clinical efficacy.